Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Colorectal Cancer Reports
Erschienen in: Current Colorectal Cancer Reports 6/2016

20.09.2016 | Molecular Epidemiology (L Jiao and CR Daniel-MacDougall, Section Editors)

Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective

verfasst von: Upender Manne, Trafina Jadhav, Balananda-Dhurjati Kumar Putcha, Temesgen Samuel, Shivani Soni, Chandrakumar Shanmugam, Esther A. Suswam

Erschienen in: Current Colorectal Cancer Reports | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

This review provides updates on the efforts for the development of prognostic and predictive markers in colorectal cancer based on the race/ethnicity of patients. Since the clinical consequences of genetic and molecular alterations differ with patient race and ethnicity, the usefulness of these molecular alterations as biomarkers needs to be evaluated in different racial/ethnic groups. To accomplish personalized patient care, a combined analysis of multiple molecular alterations in DNA, RNA, microRNAs (miRNAs), metabolites, and proteins in a single test is required to assess disease status in a precise way. Therefore, a special emphasis is placed on issues related to utility of recently identified genetic and molecular alterations in genes, miRNAs, and various “-omes” (e.g., proteomes, kinomes, metabolomes, exomes, methylomes) as candidate molecular markers to determine cancer progression (disease recurrence/relapse and metastasis) and to assess the efficacy of therapy in colorectal cancer in relation to patient race and ethnicity. This review will be useful for oncologists, pathologists, and basic and translational researchers.
Literatur
1.
Marcella S, Miller JE. Racial differences in colorectal cancer mortality. The importance of stage and socioeconomic status. J Clin Epidemiol. 2001;54:359–66.PubMedCrossRef
2.
3.
Ashktorab H et al. High incidence of microsatellite instability in colorectal cancer from African Americans. Clin Cancer Res. 2003;9:1112–7.PubMed
4.
Bovell LC et al. The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer. Clin Cancer Res. 2013;19:3955–65.PubMedPubMedCentralCrossRef
5.
Katkoori VR et al. Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res. 2009;15:2406–16.PubMedPubMedCentralCrossRef
6.
Manne U et al. Nuclear accumulation of p53 in colorectal adenocarcinoma: prognostic importance differs with race and location of the tumor. Cancer. 1998;83:2456–67.PubMedCrossRef
7.
Shiao YH, Chen VW, Scheer WD, Wu XC, Correa P. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res. 1995;55:1485–90.PubMed
8.
Martin DN et al. Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS One. 2009;4, e4531.PubMedPubMedCentralCrossRef
9.
Brim H et al. SLC5A8 gene, a transporter of butyrate: a gut flora metabolite, is frequently methylated in African American colon adenomas. PLoS One. 2011;6, e20216.PubMedPubMedCentralCrossRef
10.
Marsoni S, International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. Semin Oncol. 2001;28(1):14–9.PubMedCrossRef
11.
Atkinson AJ, NCI-FDA Biomarkers Definitions Working Group, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.CrossRef
12.
Catenacci DV. Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol. 2015;9:967–96.PubMedCrossRef
13.
Tutar L, Tutar E, Tutar Y. MicroRNAs and cancer; an overview. Curr Pharm Biotechnol. 2014;15:430–7.PubMedCrossRef
14.
Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014;11:145–56.PubMedCrossRef
15.
16.
17.
18.
Michael MZ, O’Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res: MCR. 2003;1:882–91.PubMed
19.
Volinia S et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257–61.PubMedPubMedCentralCrossRef
20.
Nagel R et al. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 2008;68:5795–802.PubMedCrossRef
21.
Ng EK et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58:1375–81.PubMedCrossRef
22.
Huang Z et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127:118–26.PubMedCrossRef
23.
24.
Schetter AJ et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299:425–36.PubMedPubMedCentral
25.
26.
Komatsu S et al. Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. Anticancer Res. 2013;33:271–6.PubMed
27.
Kanaan Z et al. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg. 2012;256:544–51.PubMedCrossRef
28.
29.
Li E et al. Differential expression of miRNAs in colon cancer between African and Caucasian Americans: implications for cancer racial health disparities. Int J Oncol. 2014;45:587–94.PubMedPubMedCentral
30.
Huynh C et al. Efficient in vivo microRNA targeting of liver metastasis. Oncogene. 2011;30:1481–8.PubMedCrossRef
31.
Brunet Vega A et al. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep. 2013;30:320–6.PubMed
32.
Ahmed FE et al. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool. I. Proof of principle. Cancer Genomics Proteomics. 2013;10:93–113.PubMed
33.
Qian J, Jiang B, Li M, Chen J, Fang M. Prognostic significance of microRNA-16 expression in human colorectal cancer. World J Surg. 2013;37:2944–9.PubMedCrossRef
34.
Pu XX et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010;25:1674–80.PubMedCrossRef
35.
Zhan JF et al. A functional variant in microRNA-196a2 is associated with susceptibility of colorectal cancer in a Chinese population. Arch Med Res. 2011;42:144–8.PubMedCrossRef
36.
Srivastava K, Srivastava A. Comprehensive review of genetic association studies and meta-analyses on miRNA polymorphisms and cancer risk. PLoS One. 2012;7, e50966.PubMedPubMedCentralCrossRef
37.
Lv M et al. Association between genetic variants in pre-miRNA and colorectal cancer risk in a Chinese population. J Cancer Res Clin Oncol. 2013;139:1405–10.PubMedCrossRef
38.
Azimzadeh P et al. Association of polymorphisms in microRNA-binding sites and colorectal cancer in an Iranian population. Cancer Genet. 2012;205:501–7.PubMedCrossRef
39.
Liu XX et al. Quantitative assessment of the association between genetic variants in microRNAs and colorectal cancer risk. Biomed Res Int. 2015;2015:276410.PubMedPubMedCentral
40.
Rossi L, Bonmassar E, Faraoni I. Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res. 2007;56:248–53.PubMedCrossRef
41.
Borralho PM et al. MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J. 2009;276:6689–700.PubMedCrossRef
42.
43.
Song B et al. miR-192 regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clin Cancer Res. 2008;14:8080–6.PubMedPubMedCentralCrossRef
44.
Sebio A et al. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Pharmacogenet Genomics. 2013;23:142–7.PubMedCrossRef
45.
Pardini B et al. Variation within 3′-UTRs of base excision repair genes and response to therapy in colorectal cancer patients: a potential modulation of microRNAs binding. Clin Cancer Res. 2013;19:6044–56.PubMedCrossRef
46.
47.
Chen SX et al. Identification of colonic fibroblast secretomes reveals secretory factors regulating colon cancer cell proliferation. J Proteomics. 2014;110:155–71.PubMedCrossRef
48.
Fearon ER et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science. 1990;247:49–56.PubMedCrossRef
49.
Jen J et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 1994;331:213–21.PubMedCrossRef
50.
Benatti P et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res. 2005;11:8332–40.PubMedCrossRef
51.
Brim H et al. Genomic aberrations in an African American colorectal cancer cohort reveals a MSI-specific profile and chromosome X amplification in male patients. PLoS One. 2012;7, e40392.PubMedPubMedCentralCrossRef
52.
Nayani R, Ashktorab H, Brim H, Laiyemo AO. Genetic basis for colorectal cancer disparities. Curr Color Cancer Rep. 2015;11:408–13.CrossRef
53.
Lung FW, Lee TM, Shu BC, Chang FH. p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J Cancer Res Clin Oncol. 2004;130:728–32.PubMedCrossRef
54.
Wu X et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst. 2002;94:681–90.PubMedCrossRef
55.
Dastjerdi MN. TP53 codon 72 polymorphism and P53 protein expression in colorectal cancer specimens in Isfahan. Acta Med Iran. 2011;49:71–7.PubMed
56.
Abboud R, Pai R, Picus J, Hall-Daniels LE, Suresh R, Wang-Gillam A, Sorscher S, Tan BR. Demographic factors on the incidence of KRAS mutation in colorectal cancers. In 2010 ASCO Annual Meeting Abstracts. 2010;28 no. 15_suppl e14040.
57.
Samowitz WS et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005;65:6063–9.PubMedCrossRef
58.
59.
Rozek LS et al. Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomark Prev. 2010;19:838–43.CrossRef
60.
English DR et al. Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomark Prev. 2008;17:1774–80.CrossRef
61.
Raskin L, Dakubo JC, Palaski N, Greenson JK, Gruber SB. Distinct molecular features of colorectal cancer in Ghana. Cancer Epidemiol. 2013;37:556–61.PubMedPubMedCentralCrossRef
62.
Umar A et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–8.PubMedPubMedCentralCrossRef
63.
Boland CR et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248–57.PubMed
64.
Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363:558–61.PubMedCrossRef
65.
66.
Staff PO. Correction: influence of race on microsatellite instability and CD8+ T cell infiltration in colon cancer. PLoS One. 2014;9, e103699.CrossRef
67.
Merok MA et al. Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann Oncol. 2013;24:1274–82.PubMedCrossRef
68.
Dietmaier W et al. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res. 1997;57:4749–56.PubMed
69.
Poynter JN et al. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomark Prev. 2008;17:3208–15.CrossRef
70.
Wei W et al. Racial differences in MLH1 and MSH2 mutation: an analysis of yellow race and white race based on the InSiGHT database. J Bioinforma Comput Biol. 2010;8 Suppl 1:111–25.CrossRef
71.
72.
Laken SJ et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet. 1997;17:79–83.PubMedCrossRef
73.
Rozen P et al. Prevalence of the I1307K APC gene variant in Israeli Jews of differing ethnic origin and risk for colorectal cancer. Gastroenterology. 1999;116:54–7.PubMedCrossRef
74.
Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–34.PubMedCrossRef
75.
Roth AD et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. J Clin Oncol. 2010;28:466–74.PubMedCrossRef
76.
Prahallad A et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100–3.PubMedCrossRef
77.
78.
Raida M et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res. 2001;7:2832–9.PubMed
79.
80.
Russo A et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol. 2005;23:7518–28.PubMedCrossRef
81.
Rouits E et al. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res. 2004;10:5151–9.PubMedCrossRef
82.
Palomaki GE, Bradley LA, Douglas MP, Kolor K, Dotson WD. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med. 2009;11:21–34.PubMedPubMedCentralCrossRef
83.
Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 2001;61:900–2.PubMed
84.
Leung WK et al. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol. 2005;100:2274–9.PubMedCrossRef
85.
Church TR et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317–25.PubMedCrossRef
86.
Ezzeldin HH, Lee AM, Mattison LK, Diasio RB. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res. 2005;11:8699–705.PubMedCrossRef
87.
Amstutz U, Farese S, Aebi S, Largiader CR. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. J Exp Clin Cancer Res. 2008;27:54.PubMedPubMedCentralCrossRef
88.
Xia YY et al. Racial/ethnic disparities in human DNA methylation. Biochim Biophys Acta. 2014;1846:258–62.PubMed
89.
Shen L et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A. 2007;104:18654–9.PubMedPubMedCentralCrossRef
90.
Samowitz WS et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005;129:837–45.PubMedCrossRef
91.
Ward RL et al. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol. 2003;21:3729–36.PubMedCrossRef
92.
93.
Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomark Prev. 2007;16:2533–47.CrossRef
94.
Sinicrope FA, Foster NR, Sargent DJ, O’Connell MJ, Rankin C. Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res. 2010;16:1884–93.PubMedPubMedCentralCrossRef
95.
Monda KL et al. A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet. 2013;45:690–6.PubMedPubMedCentralCrossRef
96.
97.
Manne U, Shanmugam C, Katkoori VR, Bumpers HL, Grizzle WE. Development and progression of colorectal neoplasia. Cancer Biomark. 2010;9:235–65.PubMedPubMedCentral
98.
Chatla C et al. Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinoma. Cancer Biomark. 2005;1:241–50.PubMedPubMedCentral
99.
Chen Z et al. Prognostic value and clinicopathological differences of HIFs in colorectal cancer: evidence from meta-analysis. PLoS One. 2013;8, e80337.PubMedPubMedCentralCrossRef
100.
101.
Ballesta AM, Molina R, Filella X, Jo J, Gimenez N. Carcinoembryonic antigen in staging and follow-up of patients with solid tumors. Tumour Biol. 1995;16:32–41.PubMedCrossRef
102.
Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem. 2001;47:624–30.PubMed
103.
Loewenstein MS, Zamcheck N. Carcinoembryonic antigen (CEA) levels in benign gastrointestinal disease states. Cancer. 1978;42:1412–8.PubMedCrossRef
104.
Seki K et al. Serum lactate dehydrogenase levels as a predictive marker of oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci. 2014;11:641–5.PubMedPubMedCentralCrossRef
105.
Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291:585–90.PubMedCrossRef
106.
Ognjanovic S et al. Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multiethnic population. Cancer Causes Control. 2010;21:1131–8.PubMedCrossRef
107.
Wang G et al. A prospective follow-up study of the relationship between C-reactive protein and human cancer risk in the Chinese Kailuan Female Cohort. Cancer Epidemiol Biomarkers Prev. 2015;24:459–65.PubMedCrossRef
108.
Wu J et al. Circulating C-reactive protein and colorectal cancer risk: a report from the Shanghai Men’s Health Study. Carcinogenesis. 2013;34:2799–803.PubMedPubMedCentralCrossRef
109.
Chew MH, Koh P, Tan M, Lim KH, Carol L, Tang CL. Mismatch repair deficiency screening via immunohistochemical staining in young Asians with colorectal cancers. World J Surg. 2013;37:2468–75.PubMedCrossRef
110.
Lu Y, Zhuo C, Cui B, et al. TYMS serves as a prognostic indicator to predict the lymph node metastasis in Chinese patients with colorectal cancer. Clin Biochem. 2013;46:1478–83.PubMedCrossRef
111.
Qiu Y et al. Prevalence and molecular characterisation of the sessile serrated adenoma in a subset of the Chinese population. J Clin Pathol. 2014;67:491–8.PubMedCrossRef
112.
Itzkowitz S et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol. 2008;103:2862–70.PubMedCrossRef
113.
Wang Y et al. Gene expression profiles and molecular markers to predict recurrence of Dukes’ B colon cancer. J Clin Oncol. 2004;22:1564–71.PubMedCrossRef
114.
Eschrich S et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005;23:3526–35.PubMedCrossRef
115.
Kennedy RD et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol. 2011;29:4620–6.PubMedCrossRef
116.
Sveen A et al. ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients. Clin Cancer Res. 2012;18:6001–10.PubMedCrossRef
117.
Maak M et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg. 2013;257:1053–8.PubMedCrossRef
118.
Govindarajan R et al. A comparison of 12-gene colon cancer assay gene expression in African American and Caucasian patients with stage II colon cancer. BMC Cancer. 2016;16:368.PubMedPubMedCentralCrossRef
119.
120.
121.
Ogino S et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005;11:6650–6.PubMedCrossRef
122.
123.
Pan BT, Johnstone RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 1983;33:967–78.PubMedCrossRef
124.
Zduriencikova M, Gronesova P, Cholujova D, Sedlak J. Potential biomarkers of exosomal cargo in endocrine signaling. Endocr Regul. 2015;49:141–50.PubMedCrossRef
125.
Taylor DD, Gercel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer. 2005;92:305–11.PubMedPubMedCentral
126.
127.
Park JE et al. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics. 2010;9:1085–99.PubMedPubMedCentralCrossRef
128.
129.
Komatsu S et al. Circulating miR-18a: a sensitive cancer screening biomarker in human cancer. In Vivo (Athens, Greece). 2014;28:293–7.
130.
131.
132.
Ji H et al. Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics. 2013;13:1672–86.PubMedCrossRef
133.
134.
135.
Choi DS et al. Proteomic analysis of microvesicles derived from human colorectal cancer ascites. Proteomics. 2011;11:2745–51.PubMedCrossRef
136.
Wishart DS et al. HMDB 3.0—the Human Metabolome Database in 2013. Nucleic Acids Res. 2013;41:D801–7.PubMedCrossRef
137.
Malet-Martino M, Holzgrabe U. NMR techniques in biomedical and pharmaceutical analysis. J Pharm Biomed Anal. 2011;55:1–15.PubMedCrossRef
138.
139.
140.
Mal M, Koh PK, Cheah PY, Chan EC. Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry. Anal Bioanal Chem. 2012;403:483–93.PubMedCrossRef
141.
Ma Y et al. An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer. Ann Surg. 2012;255:720–30.PubMedCrossRef
142.
Cheng Y et al. Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012;11:1354–63.PubMedCrossRef
143.
Bertini I et al. Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res. 2012;72:356–64.PubMedCrossRef
144.
Ritchie SA et al. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010;8:13.PubMedPubMedCentralCrossRef
145.
Ong ES et al. Metabolic profiling in colorectal cancer reveals signature metabolic shifts during tumorigenesis. Mol Cell Proteomics. 2010.
146.
Ma Y et al. A pilot study of gas chromatograph/mass spectrometry-based serum metabolic profiling of colorectal cancer after operation. Mol Biol Rep. 2010;37:1403–11.PubMedCrossRef
147.
Monleon D et al. Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009;22:342–8.PubMedCrossRef
148.
Ikeda A et al. Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr: BMC. 2012;26:548–58.PubMedCrossRef
149.
Batty CA, Cauchi M, Lourenco C, Hunter JO, Turner C. Use of the analysis of the volatile faecal metabolome in screening for colorectal cancer. PLoS One. 2015;10, e0130301.PubMedPubMedCentralCrossRef
150.
Cross AJ et al. A prospective study of serum metabolites and colorectal cancer risk. Cancer. 2014;120:3049–57.PubMedCrossRef
151.
152.
Zackular JP, Rogers MA, Ruffin MTT, Schloss PD. The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res (Phila). 2014;7:1112–21.CrossRef
153.
154.
155.
156.
Reimers MS, Zeestraten EC, Kuppen PJ, Liefers GJ, van de Velde CJ. Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep. 2013;1:166–83.CrossRef
157.
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912–34.PubMedCrossRef
158.
159.
Schneider-Stock R, Fakhoury IH, Zaki AM, El-Baba CO, Gali-Muhtasib HU. Thymoquinone: fifty years of success in the battle against cancer models. Drug Discov Today. 2014;19:18–30.PubMedCrossRef
160.
El-Baba C et al. Thymoquinone-induced conformational changes of PAK1 interrupt prosurvival MEK-ERK signaling in colorectal cancer. Mol Cancer. 2014;13:201.PubMedPubMedCentralCrossRef
161.
162.
Tejpar S et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist. 2010;15:390–404.PubMedPubMedCentralCrossRef
163.
Alexander D et al. Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinoma. Cancer. 2004;101:66–76.PubMedPubMedCentralCrossRef
164.
Alexander D et al. High-grade tumor differentiation is an indicator of poor prognosis in African Americans with colonic adenocarcinomas. Cancer. 2005;103:2163–70.PubMedPubMedCentralCrossRef
165.
Alexander DD et al. African-American and Caucasian disparities in colorectal cancer mortality and survival by data source: an epidemiologic review. Cancer Biomark. 2007;3:301–13.PubMedPubMedCentral
Metadaten
Titel
Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective
verfasst von
Upender Manne
Trafina Jadhav
Balananda-Dhurjati Kumar Putcha
Temesgen Samuel
Shivani Soni
Chandrakumar Shanmugam
Esther A. Suswam
Publikationsdatum
20.09.2016
Verlag
Springer US
Erschienen in
Current Colorectal Cancer Reports / Ausgabe 6/2016
Print ISSN: 1556-3790
Elektronische ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-016-0338-1

Weitere Artikel der Ausgabe 6/2016

Current Colorectal Cancer Reports 6/2016 Zur Ausgabe

Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)

Ongoing Adjuvant/Neoadjuvant Trials in Resectable Metastatic Colorectal Cancer

Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)

Molecular Classification of Colon Cancer: Perspectives for Personalized Adjuvant Therapy

Localized Colorectal Cancer (RD Kim, Section Editor)

Novel Radiation Approaches for the Treatment of Rectal Cancer: Where Are We Now?

Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)

Adjuvant Chemotherapy for Colon Cancer: Guidelines and Clinical Trials in Japan

Prevention and Early Detection (R Benamouzig, Section Editor)

What Is the Best Approach to Avoid Colorectal Cancer Risk in Inflammatory Bowel Disease?

Localized Colorectal Cancer (RD Kim, Section Editor)

The Role of Adjuvant Treatment in Resected T3N0 Rectal Cancer

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

17.04.2024 | Mammakarzinom | Nachrichten

Adjuvante Brustkrebstherapie: Doppelt hält besser

16.04.2024 | HNO-Chirurgie | Nachrichten

HNO-Op. auch mit über 90?

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Manche Gestagene können das Risiko für Meningeome erhöhen
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen